SCHEMBL6153310

SCHEMBL6153310

NC(=O)c1ccc(NC2CCNCC2)cc1OC(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.48
SYK P43405 2/20 0.43
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
PLK1 P53350 1/20 0.41
CCNA1 P78396 1/20 0.41
PLK3 Q9H4B4 1/20 0.41
PLK2 Q9NYY3 1/20 0.41
KIT P10721 1/20 0.41
FLT3 P36888 1/20 0.41
RPS6KB1 P23443 2/20 0.40
AURKA O14965 1/20 0.40
CTSL P07711 2/20 0.39
CTSB P07858 2/20 0.39
CTSS P25774 2/20 0.39
CTSK P43235 2/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
P2RX7 Q99572 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153679 0.84 HTR4 (0.48) SYKCDK2KITFLT3RPS6KB1
SCHEMBL6153513 0.81 SYK (0.46) SYKCDK2KITFLT3RPS6KB1
SCHEMBL6154413 0.81 IRAK4 (0.48) MKNK1MKNK2IRAK4
SCHEMBL6154140 0.80 HTR4 (0.45) SYKCDK2KITFLT3RPS6KB1
SCHEMBL6156769 0.80 ROCK2 (0.47) SYKRPS6KB1AURKASIRT2P2RX7
SCHEMBL6155360 0.79 MAPT (0.46) SYKCDK2KITFLT3RPS6KB1
SCHEMBL6153421 0.78 AURKA (0.45) SYKFLT3RPS6KB1AURKASIRT2
SCHEMBL6153705 0.78 LTA4H (0.48)
Trifluoroacetic Acid SCHEMBL6156921 0.78 CACNA1B (0.45) EPHX1CDK2FLT3RPS6KB1AURKA
SCHEMBL6155049 0.77 FLT3 (0.44) SYKKITFLT3RPS6KB1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 EPHX1 1073/4885SYK 1613/4885CCNA2 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.